Pfizer Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
Pfizer Inc. (NYSE: PFE) announced today that the PROFILE 1007 study met its primary endpoint, demonstrating that XALKORI® (crizotinib) significantly improved progression-free survival (PFS) when compared with pemetrexed or docetaxel, in previously treated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). PROFILE 1007 is the first randomized Phase 3 study in ALK-positive advanced NSCLC patients.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.